Nuvalent, Inc. (NUVL)
103.87
-1.56
(-1.48%)
USD |
NASDAQ |
Apr 06, 15:57
Nuvalent SG&A Expense (TTM) : 107.34M for Dec. 31, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Glaukos Corp. | 331.75M |
| Edgewise Therapeutics, Inc. | 40.02M |
| Cogent Biosciences, Inc. | 63.58M |
| Neurocrine Biosciences, Inc. | 1.156B |
| Arcellx, Inc. | 117.76M |